Sessions

Aug 17-18, 2023    Paris, France
3rd International Conference on

Immunology and Allergic Diseases

Sessions

Allergy and Clinical Immunology

The potential for precision medicine in food allergy, drug allergy, and anaphylaxis under the auspices of the PRACTALL collaboration platform. PRACTALL is a joint effort of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology, which aims to synchronize the European and American approaches to allergy care. Progress has been made in discovery of biomarkers to guide a precision medicine approach to treatment of food and drug allergy, but further validation and quantification of these biomarkers are needed to allow their translation into practice in the clinical management of allergic disease.

Allergy Immunotherapy and Pediatric Immunology

 

Allergy immunotherapy (AIT) is an effective treatment for allergic asthma and rhinitis, as well as venom-induced anaphylaxis. In addition to reducing symptoms, AIT can change the course of allergic disease and induce allergen-specific immune tolerance. In current clinical practice immunotherapy is delivered either subcutaneously or sublingually; some allergens, such as grass pollen, can be delivered through either route, whereas others, such as venoms, are only delivered subcutaneously. Both subcutaneous and sublingual immunotherapy appear to have a duration of efficacy of up to 12 years, and both can prevent the development of asthma and new allergen sensitivities.

A child experiencing sensitivities or different issues with his safe framework is alluded as pediatric immunology. Youngster's invulnerable framework battles against contaminations. Assuming the kid has sensitivities, their invulnerable framework wrongly responds to things that are normally innocuous. Pet dander, dust, dust, form spores, bug stings, food, and drugs are instances of things like this. This response might cause their body to react with medical issues like asthma, roughage fever, hives, dermatitis (a rash), or an exceptionally extreme and surprising response called hypersensitivity. .

Sublingual Immunotherapy in Allergic Rhinitis Children

Sublingual immunotherapy (SLIT) had good effectiveness for children with allergic rhinitis (AR). However, no studies explored the effect of persistent allergen exposure on SLIT treatment. Coronavirus disease 2019 (COVID-19) restricts outdoor activities of children significantly. We aimed to evaluate the effectiveness of SLIT during this special period. results suggest that continuous HDM exposure reduced the effectiveness of SLIT, whereas effective reduction of HDM levels by frequent bed cleaning will be helpful during the SLIT treatment.

Microbiome in Allergic Disease

PRACTALL is a joint initiative of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology to provide shared evidence-based recommendations on cutting-edge topics in the field of allergy and immunology. PRACTALL 2017 is focused on what has been established regarding the role of the microbiome in patients with asthma, atopic dermatitis, and food allergy. This is complemented by outlining important knowledge gaps regarding its role in allergic disease and delineating strategies necessary to fill these gaps. In addition, a review of progress in approaches used to manipulate the microbiome will be addressed, identifying what has and has not worked to serve as a baseline for future directions to intervene in allergic disease development, progression, or both.

Priorities in Rhinitis and Rhinosinusitis

The first European Rhinology Research Forum organized by the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) was held in the Royal Academy of Medicine in Brussels on 17th and 18th November 2016, in collaboration with the European Rhinologic Society (ERS) and the Global Allergy and Asthma European Network (GA2LEN). This is thoroughly integrated in the context of Precision Medicine (PM), with personalized care, prediction of success of treatment, participation of the patient and prevention of disease as key principles for improving current clinical practices. This report provides a concise summary of the outcomes of the brainstorming sessions of the European Rhinology Research Forum 2016.

From Rhinitis Phenotype to Disease Spectrum

Local respiratory allergy (LRA) is defined by the negativity of atopy tests, a clinical history suggestive of airway allergy and a positive response to the nasal and/or bronchial allergen challenge. The clinical spectrum of LRA is comprised of three conditions: local allergic rhinitis (LAR) and local allergic asthma in non-atopic patients, and dual allergic rhinitis (coexistence of allergic rhinitis and LAR) in atopic individuals. LRA is an independent disease phenotype not progressing to atopy over time, but naturally evolving to the clinical worsening and the onset of comorbidities. Published data suggests that LRA is mediated through the mucosal synthesis of allergen-specific (s)IgE, which binds to FcϵRI on resident mast cells, and in >50% of cases traffics to the blood stream to sensitize circulating basophils.

Immunotherapy for Pediatric Respiratory Allergy

Allergic respiratory diseases are major health problems in paediatric population due their high level of prevalence and chronicity, and to their relevance in the costs and quality of life. One of the most important risk factors for the development of airway diseases in children and adolescents is atopy. The mainstays for the treatment of these diseases are avoiding allergens, controlling symptoms, and preventing them through sustained desensitization by allergen immunotherapy (AIT). In addition, it is considered the only treatment that can influence the natural course of the disease by targeting the cause of the allergic inflammatory response. The aim of this publication is to reflect the advances of AIT in the diagnosis and treatment of allergic respiratory diseases in children and adolescents reviewing articles published since 2000, establishing evidence categories to support the strength of the recommendations based on evidence.

Allergy, Hypersensitivity and Asthma

Allergies are classified as TYPE I responses by Gell and Coombs. IgE Antibodies, which are suited for the official to Fc-receptors for IgE on tissue Mast Cells, are responsible for the majority of cases. Pole cell Degranulation is caused by the cross-connection of these layers bound IgE's by a specific antigen; this procedure releases Histamine and a variety of other effector chemicals, resulting in the sensitivity bunch adverse effects. (Rashes, food poisoning, asthma, and so on.) The Prausnitz-Küstner (P-K) skin response in people and the passive cutaneous hypersensitivity (PCA) in guinea pigs provide models for studying the basic component of unfavourably sensitive responses. Sensitivity management begins with allergy avoidance and includes the use of a variety of medicines as well as allergen-specific desensitisation.

Asthma is a chronic lung illness that affects the airways. The bronchial tubes, or airways, allow air to enter and exit the lungs. A mix of genetic and environmental variables is thought to be the cause of asthma. Airway inflammation and constriction are the two major symptoms of asthma. Both ingredients have an effect on your lungs' airways, making breathing more difficult. Asthma is a chronic illness that cannot be cured, although it can be controlled. Other health issues, such as gastro-esophageal reflux disease (GERD), rhinosinusitis, and obstructive sleep apnea, are more common in asthmatics. Recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing are all symptoms of asthma. Sputum can come from the lungs by coughing but is often hard to bring up.

Cancer Immunotherapy and Auto Immune Disorder

One type of cancer treatment is immunotherapy. It makes use of chemicals produced by the body or in a lab to strengthen the immune system and assist the body in locating and eliminating cancer cells. Numerous forms of cancer can be treated using immunotherapy. It may be used alone or in conjunction with other cancer treatments such as chemotherapy.An immune system infection creates when your invulnerable framework, which safeguards your body against sickness, concludes your sound cells are unfamiliar. Subsequently, your invulnerable framework assaults sound cells.

Auto Immune Disorder is an immune system issue might bring about the annihilation of body tissue, unusual development of an organ, Changes in organ work. Contingent upon the kind, an immune system infection can influence one or a wide range of sorts of body tissue. Regions regularly impacted via immune system issues incorporate Blood vessels, Connective tissues, Endocrine organs, for example, the thyroid or pancreas, Joints Muscles, Red platelets, Skin It can likewise cause strange organ development and changes in organ work. There are upwards of 80 sorts of immune system sicknesses. A considerable lot of them have comparative side effects, which makes them undeniably challenging to analyze. It's additionally conceivable to have more than one simultaneously. Normal immune system problems incorporate Addison's infection, Dermatomyositis, Graves' illness, Hashimoto's thyroiditis, Multiple sclerosis, Myasthenia gravis, Pernicious sickliness, Reactive joint inflammation. Immune system sicknesses as a rule change between times of abatement (practically zero manifestations) and eruptions (deteriorating side effects). Right now, treatment for immune system sicknesses centers around assuaging manifestations since there is no remedial treatment.

 

  • Disease and Autoimmunity
  • Antinuclear antibodies (ANA) immunofluorescence
  • Offsetting resistant homeostasis with effector and administrative T cells
  • Epigenetic control of immune system infections
  • Curiosities in Autoimmunity
  • Advancement developments in understanding pathogenesis of infection

Global Immunology Market Trends and R&D

The global immunology market size was USD 85.74 billion in 2020. The global impact of COVID-19 has been unprecedented and staggering, with immunology drugs witnessing a negative impact on demand across all regions amid the pandemic. Based on our analysis, the global market exhibited a lower growth of 4.2% in 2020 compared to the average year-on-year growth during 2017-2020. The market is projected to grow from USD 92.00 billion in 2021 to USD 158.69 billion in 2028 at a CAGR of 8.1% during the 2021-2028 period. The sudden rise in CAG is attributable to this market's demand and growth, returning to pre-pandemic levels once the pandemic is over. Immunology drugs or agents modify the immune response, either by enhancing or suppressing the immune system. They are used to fight infections, prevent or treat certain autoimmune or immunological disorders. The rise in awareness regarding immunological diseases in both developing and developed nations and the growing prevalence of immunological disorders due to environmental factors are the critical reasons propelling the growth of the global market. Moreover, existing market players operating in the global market focus on constant innovation and upgrading their product portfolio for better treatment outcomes for the patients. This is anticipated to augment the market growth during the forecast period

  [email protected]
  [email protected]
  [email protected]
Speakers Interview